SAN DIEGO, CA June 26-27, 2017 – Bainbridge Strategy Consulting announces a successful attendance to the 2017 Festival of Genomics conference at the downtown San Diego convention center. Festival of Genomics celebrates scientists and thought leaders coming together to contribute their insights to a variety of topics from genome therapy services to personalized medicine.
Bainbridge recognizes the massive amount of growth that is occurring in the genomics space. We interacted with industry leaders and heard first-hand how certain genome medicines are impacting the healthcare system through genome testing. Some key takeaways to consider were of high interest to many conference attendees like targeted therapy and precision medicine.
With precision oncology, the patient’s genetic data is carefully analyzed to create treatments that accurately target and improve their specific need. There are over 200 different cancer diseases that can vary between persons and even patients with the same type of cancer. So, one treatment will not be the right fit for every person with the same type of cancer disease. Precision oncology is a trend that is occurring in the research and clinical community due to the extremely precise mechanisms that will define the causes for specific types of cancer.
In the most recent issue of Front Line Genomics Magazine, Ann Bode, Editor-in-Chief of NPJ Precision Oncology stated in an interview that the three central pillars of precision oncology include “precision diagnosis, precision prevention, and precision therapy.” This is the era of targeted cancer therapy where drugs can be matched to a tumor’s specific genetic mutations.
The most prominent challenge in genome medicine is the cost of production. An important example of this problem is in personalized medicine – an expensive technique that is available, but does appeal to consumers. Companies like HNX Health Nucleus offer microbiome sequencing, however, the costs begin at $500 and can go as high as $25,000.
It is often heard that there is more genetic data being produced than ever before. The next question to ask is, what can scientists do with it? That’s where computational biology and bioinformaticians are needed the most. Scientist are now considering machine learning but only in cases that have a well-defined problem and a large data set. Most data sets, especially in oncology, are small and include only five to ten samples from one study, which is not enough for a machine learning program to process. Nevertheless, a survey produced by Medscape claims 89% of the participating oncologists believe genomic tests will be very useful within the next decade. The Festival of Genomics is a premier hub for learning the technical and economic value behind the future of this industry.